Precision oncology, from block to report
Whole exome sequencing analysis services that identify cancer-associated variants, hereditary cancer risk and actionable, precision-oncology findings.
Download the Clinical Cancer Genomics brochure (PDF)
Genes covered include
Deliverables: variant summary, clinical significance, ACMG classification, literature-supported findings, risk assessment and therapeutic implications.
Sample reports
De-identified real case output. Click to preview.
Click a test to see what it covers.
Comprehensive Genomic Profiling (CGP)FFPE / BloodRs. 97,000–115,000
Sequences and analyzes 562 genes associated with solid tumors — SNVs, indels, CNVs, select fusions and genomic signatures, reported against an ACMG-aligned classification framework.
HRD-50 AnalysisFFPE / BloodRs. 100,000–116,000
Not a fixed gene panel — HRD is a genome-wide scarring signature. The Genomic Instability Score (GIS) combines three components measured across the genome: LOH (loss of heterozygosity) + TAI (telomeric allelic imbalance) + LST (large-scale state transitions). A GIS ≥42 is reported HRD-positive, interpreted alongside BRCA1/BRCA2 mutation status to flag PARP-inhibitor and platinum-chemotherapy sensitivity.
BRCA1 & BRCA2 AnalysisFFPE / BloodRs. 98,000–114,000
Genes: BRCA1, BRCA2. Full coding-region and splice-site coverage for germline or somatic pathogenic variants informing hereditary breast/ovarian cancer risk and PARP-inhibitor eligibility.
Microsatellite Instability (MSI)FFPE / BloodRs. 112,000–130,000
Mismatch-repair genes assessed: MLH1, MSH2, MSH6, PMS2 (plus the EPCAM regulatory region). Identifies MSI-High / dMMR tumors eligible for checkpoint-inhibitor immunotherapy.
Tumor Mutational Burden (TMB)FFPE / BloodRs. 117,000–135,000
Computed genome-wide from the sequencing data (mutations per megabase) rather than a fixed gene list — high TMB is an independent biomarker for immune checkpoint inhibitor response.
Germline Hereditary Cancer PanelBloodRs. 120,000
Clinically actionable hereditary cancer genes selected per NCCN hereditary testing criteria, including BRCA1, BRCA2, TP53, PALB2, ATM, CHEK2, MLH1, MSH2, MSH6, PMS2, APC, MUTYH, PTEN, STK11, CDH1 and others.
Precision Oncology Clinical ReportFFPE TissueRs. 147,000
Not a standalone test — a synthesized clinical report integrating CGP, HRD and biomarker findings (MSI, TMB) into a single ACMG-classified, therapy-oriented summary for the treating oncologist.
Tumor-type genomic panels (lung, breast, ovarian, colorectal, pancreatic, prostate, gastric, melanoma) — Rs. 145,000 each, FFPE tissue, 5-week TAT.
Sample reports, in detail
Real NCRO case output, de-identified — all patient, physician and institution details removed. Shown to illustrate report depth and format; click a case to expand.
Case A — High-Grade Serous Carcinoma CGP + HRD · FFPE & Blood PIK3CA positive · HRD positive
PIK3CA pathogenic finding, HRD-positive (GIS 95/100). De-identified — patient, physician and institution details removed.
Case B — Peritoneal / Omental Deposit HRD only HRD positive
HRD-only analysis, HRD-positive (GIS 69/100). De-identified — patient, physician and institution details removed.
Case C — Serous Carcinoma CGP + HRD Two VUS findings · HRD positive
Clean CGP with two VUS findings, HRD-positive (GIS 51/100). De-identified — patient, physician and institution details removed.
Sample collection
Patient blood or tissue received
DNA extraction & QC
High-quality DNA extracted and evaluated
Whole exome sequencing
All protein-coding regions sequenced
Bioinformatics analysis
Computational variant identification
Clinical interpretation
Variant annotation, significance assessment
Comprehensive reporting
Customized report per client requirements
Whole blood (germline)
- 3–5 mL peripheral blood
- EDTA (purple-top) tube
- Store at 2–8°C
- Ship within 48 hours
FFPE tissue (block)
- Submit clearly labeled block
- Include pathology report if available
- Somatic variant / solid tumor profiling
Fresh tissue
- Sterile container
- Keep chilled, 2–8°C
- Ship immediately
- Avoid freeze-thaw cycles
Purified DNA
- ≥500 ng high-quality genomic DNA
- A260/A280 ratio 1.8–2.0
- Concentration ≥20 ng/µL
Search the gene panel database
4,953 unique genes across NCRO's nine curated panels — PanCancer Pro, Hemato Pro, Fusion Pro, ClinEX Pro, Heva Pro, IVF Pro, HRD Pro, Cardio Pro, Neoscreen Pro — each with its clinical or research significance and, where one exists, the FDA-approved drug or NCCN-aligned clinical management implication. Want to build a custom Sanger, PCR or NGS order around specific genes or exons, or get an instant priced quote? Visit NCRO Biotools (login required).
Open the full gene panel database →Clinical Pathologist Sign-out
Clinical data analysis for BRaCA panel (4eVAR CE-IVD approved)
Clinical data analysis for ClinEX pro (4eVAR CE-IVD Approved)
Clinical data analysis for HRD pro (4eVAR CE-IVD approved)
Clinical data analysis for WholEX pro (4eVAR CE-IVD Approved)
Clinical data analysis for panCancer pro (4eVAR CE-IVD Apprved)
You might also need
Book a free consultation
Send us a brief overview of your project — our scientific team will review it and get back with a proposal.